An ancestral SARS-CoV-2 vaccine induces anti-Omicron variants antibodies by hypermutation

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

Extent: 1 Online-Ressource.

Language: Englisch

Bibliographic citation: An ancestral SARS-CoV-2 vaccine induces anti-Omicron variants antibodies by hypermutation ; volume:15 ; number:1 ; day:20 ; month:4 ; year:2024 ; pages:1-9 ; date:12.2024
Nature Communications ; 15, Heft 1 (20.4.2024), 1-9, 12.2024

Creator: Park, Seoryeong
Choi, Jaewon
Lee, Yonghee
Noh, Jinsung
Kim, Namphil
Lee, JinAh
Cho, Geummi
Kim, Sujeong
Yoo, Duck Kyun
Kang, Chang Kyung
Choe, Pyoeng Gyun
Kim, Nam Joong
Park, Wan Beom
Kim, Seungtaek
Oh, Myoung-don
Kwon, Sunghoon
Chung, Junho

Contributor: SpringerLink (Online service)

DOI: 10.1038/s41467-024-47743-1

URN: urn:nbn:de:101:1-2407022100417.407206697822

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 10:50 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Park, Seoryeong
Choi, Jaewon
Lee, Yonghee
Noh, Jinsung
Kim, Namphil
Lee, JinAh
Cho, Geummi
Kim, Sujeong
Yoo, Duck Kyun
Kang, Chang Kyung
Choe, Pyoeng Gyun
Kim, Nam Joong
Park, Wan Beom
Kim, Seungtaek
Oh, Myoung-don
Kwon, Sunghoon
Chung, Junho
SpringerLink (Online service)

Other Objects (12)

A self-assembled trimeric protein vaccine induces protective immunity against Omicron variant

Reduced neutralization of SARS-CoV-2 Omicron variant by vaccine sera and monoclonal antibodies

Repeated Omicron exposures override ancestral SARS-CoV-2 immune imprinting

Intranasal adenovirus-vectored Omicron vaccine induced nasal immunoglobulin A has superior neutralizing potency than serum antibodies

Combating the SARS-CoV-2 Omicron (BA.1) and BA.2 with potent bispecific antibodies engineered from non-Omicron neutralizing antibodies

Bivalent mRNA vaccine booster induces robust antibody immunity against Omicron lineages BA.2, BA.2.12.1, BA.2.75 and BA.5

BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection

Omicron-specific and bivalent omicron-containing vaccine candidates elicit potent virus neutralisation in the animal model

Clinical characteristics and booster vaccine effectiveness of the Omicron variant

Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies

Preclinical characterization of the Omicron XBB.1.5-adapted BNT162b2 COVID-19 vaccine

A self-assembled trimeric protein vaccine induces protective immunity against Omicron variant

Reduced neutralization of SARS-CoV-2 Omicron variant by vaccine sera and monoclonal antibodies

Repeated Omicron exposures override ancestral SARS-CoV-2 immune imprinting

Intranasal adenovirus-vectored Omicron vaccine induced nasal immunoglobulin A has superior neutralizing potency than serum antibodies

Combating the SARS-CoV-2 Omicron (BA.1) and BA.2 with potent bispecific antibodies engineered from non-Omicron neutralizing antibodies

Bivalent mRNA vaccine booster induces robust antibody immunity against Omicron lineages BA.2, BA.2.12.1, BA.2.75 and BA.5

BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection

Omicron-specific and bivalent omicron-containing vaccine candidates elicit potent virus neutralisation in the animal model

Clinical characteristics and booster vaccine effectiveness of the Omicron variant

Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies

Preclinical characterization of the Omicron XBB.1.5-adapted BNT162b2 COVID-19 vaccine

A self-assembled trimeric protein vaccine induces protective immunity against Omicron variant

Reduced neutralization of SARS-CoV-2 Omicron variant by vaccine sera and monoclonal antibodies

Repeated Omicron exposures override ancestral SARS-CoV-2 immune imprinting

Intranasal adenovirus-vectored Omicron vaccine induced nasal immunoglobulin A has superior neutralizing potency than serum antibodies

Combating the SARS-CoV-2 Omicron (BA.1) and BA.2 with potent bispecific antibodies engineered from non-Omicron neutralizing antibodies

Bivalent mRNA vaccine booster induces robust antibody immunity against Omicron lineages BA.2, BA.2.12.1, BA.2.75 and BA.5

BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection

Omicron-specific and bivalent omicron-containing vaccine candidates elicit potent virus neutralisation in the animal model

Clinical characteristics and booster vaccine effectiveness of the Omicron variant

Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies

Preclinical characterization of the Omicron XBB.1.5-adapted BNT162b2 COVID-19 vaccine

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read and agree to the privacy policy for the collection of personal data.*

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

An ancestral SARS-CoV-2 vaccine induces anti-Omicron variants antibodies by hypermutation

Show object

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

A self-assembled trimeric protein vaccine induces protective immunity against Omicron variant

Reduced neutralization of SARS-CoV-2 Omicron variant by vaccine sera and monoclonal antibodies

Reduced neutralization of SARS-CoV-2 Omicron variant by vaccine sera and monoclonal antibodies

Repeated Omicron exposures override ancestral SARS-CoV-2 immune imprinting

Intranasal adenovirus-vectored Omicron vaccine induced nasal immunoglobulin A has superior neutralizing potency than serum antibodies

Combating the SARS-CoV-2 Omicron (BA.1) and BA.2 with potent bispecific antibodies engineered from non-Omicron neutralizing antibodies

Bivalent mRNA vaccine booster induces robust antibody immunity against Omicron lineages BA.2, BA.2.12.1, BA.2.75 and BA.5

BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection

Omicron-specific and bivalent omicron-containing vaccine candidates elicit potent virus neutralisation in the animal model

Clinical characteristics and booster vaccine effectiveness of the Omicron variant

Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies

Preclinical characterization of the Omicron XBB.1.5-adapted BNT162b2 COVID-19 vaccine

A self-assembled trimeric protein vaccine induces protective immunity against Omicron variant

Reduced neutralization of SARS-CoV-2 Omicron variant by vaccine sera and monoclonal antibodies

Reduced neutralization of SARS-CoV-2 Omicron variant by vaccine sera and monoclonal antibodies

Repeated Omicron exposures override ancestral SARS-CoV-2 immune imprinting

Intranasal adenovirus-vectored Omicron vaccine induced nasal immunoglobulin A has superior neutralizing potency than serum antibodies

Combating the SARS-CoV-2 Omicron (BA.1) and BA.2 with potent bispecific antibodies engineered from non-Omicron neutralizing antibodies

Bivalent mRNA vaccine booster induces robust antibody immunity against Omicron lineages BA.2, BA.2.12.1, BA.2.75 and BA.5

BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection

Omicron-specific and bivalent omicron-containing vaccine candidates elicit potent virus neutralisation in the animal model

Clinical characteristics and booster vaccine effectiveness of the Omicron variant

Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies

Preclinical characterization of the Omicron XBB.1.5-adapted BNT162b2 COVID-19 vaccine

A self-assembled trimeric protein vaccine induces protective immunity against Omicron variant

Reduced neutralization of SARS-CoV-2 Omicron variant by vaccine sera and monoclonal antibodies

Reduced neutralization of SARS-CoV-2 Omicron variant by vaccine sera and monoclonal antibodies

Repeated Omicron exposures override ancestral SARS-CoV-2 immune imprinting

Intranasal adenovirus-vectored Omicron vaccine induced nasal immunoglobulin A has superior neutralizing potency than serum antibodies

Combating the SARS-CoV-2 Omicron (BA.1) and BA.2 with potent bispecific antibodies engineered from non-Omicron neutralizing antibodies

Bivalent mRNA vaccine booster induces robust antibody immunity against Omicron lineages BA.2, BA.2.12.1, BA.2.75 and BA.5

BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection

Omicron-specific and bivalent omicron-containing vaccine candidates elicit potent virus neutralisation in the animal model

Clinical characteristics and booster vaccine effectiveness of the Omicron variant

Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies

Preclinical characterization of the Omicron XBB.1.5-adapted BNT162b2 COVID-19 vaccine

Related objects

Reset password